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1. Introduction 
Hepatic encephalopathy (HE) reflects a spectrum of neuropsychiatric abnormalities seen in 
patients with liver dysfunction after exclusion of other known brain disease. 
Classification of hepatic encephalopathy is based on the clinical setting in which symptoms 
occur (Table 1).1 The encephalopathy of acute liver failure shares clinical characteristics with 
that of cirrhosis, but also exhibits unique features. In cirrhosis, three major syndromes can 
be present: 
1. Episodic (precipitant-induced) encephalopathy, commonly seen in the hospital setting, 
where a superimposed event is a key factor. 
2. Persistent (chronic) encephalopathy, seen with extensive portal–systemic shunts and 
after portocaval shunt surgery or placement of transjugular intrahepatic portosystemic 
shunt (TIPS). 
3. Minimal (subclinical) encephalopathy reflects alterations in cognitive function in 
patients who clinically exhibit a normal mental state. 
 





 Special features 
Acute liver failure  Maximal  Absent  Development of brain oedema and 
intracranial hypertension 
Cirrhosis     Low-grade cerebral oedema without 
overt signs of intracranial hypertension  
Episodic  
encephalopathy 
Variable  Variable  Precipitant induced 
Persistent 
encephalopathy 
Variable   Genarally large  Most often seen after portocaval 
surgery or TIPS 
Minimal 
encephalopathy  
Variable  Variable  Requires neuropsychological/ 
neurophysiological testing 
TIPS, transjugular intrahepatic portosystemic shunt. 
Table 1. Classification of hepatic encephalopathy. 
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Minimal hepatic encephalopathy (MHE), the mildest form of HE, is characterized by subtle 
motor and cognitive deficits, and impairs health-related quality of life (HRQOL).2 
Cirrhotic patients with MHE have a normal neurological and mental status by the standards 
of clinical examination, yet demonstrate quantifiable neuropsychological defects.3 The term 
MHE refers to the subtle changes in cognitive function, electrophysiological parameters, 
cerebral neurochemical/neurotransmitter homeostasis, cerebral blood flow, metabolism, 
and fluid homeostasis that can be observed in patients with cirrhosis who have no clinical 
evidence of hepatic encephalopathy.4  
MHE has been described previously using several different names, such as, early, low-
grade, latent or subclinical HE to identify patients with subtle cognitive function 
abnormalities. 
These subtle neurocognitive abnormalities primarily affect attention, speed of information 
processing, and motor abilities and coordination that are not recognizable on standard 
neurological examination. These neurocognitive abnormalities are independent of sleep 
dysfunction or problems with overall intelligence.5-8 
It has been well-described that MHE has a subtle but negative impact on a patient’s spatial 
skills, motor skills, the ability to perform complex tasks such as driving, and even quality of 
life.3-5 MHE predicts the development of overt HE and is associated with poor survival2. Its 
negative impact on daily living, among other reasons, has led some authors to suggest that 
the failure to diagnose this condition could be classified as a medical error.9,10 
2. Epidemiology 
There are no accurate data on the incidence of HE. HE is classified as: overt hepatic 
encephalopathy (OHE) and MHE. 
OHE occurs in 30% to 45% of cirrhotic patients11 and in 10% to 50% of patients with TIPS12 
and can be clinically diagnosed. 
The true prevalence of MHE in patients with portal hypertension is inknown. MHE has been 
diagnosed in patients with liver cirrhosis and in patients with noncirrhotic portal 
hypertension. The prevalence of MHE has been reported in as many as 20%−84% of 
cirrhotics, depending on which methods or tools are used and fixed diagnostic cut-offs.2,3 
Large variations in the prevalence of MHE are related to prior episode of OHE, severity of 
liver disease, age, preasence of esophageal varices, and surgical porto-systemic shunts. 
Patients who develop MHE are older, more often have alcohol as etiology of cirrhosis, have 
history of overt HE in the past, have more severe liver disease, and more often have 
esophagogastric varices.2,13 
3. Pathogenesis 
Despite much scientific research, the exact pathophysiological mechanisms leading to HE 
are not clearly understood. The most widely accepted theory of the pathogenesis of HE is 
that nitrogenous substances derived from the gut adversely affect the cerebral function. 
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There are various explanations why liver dysfunction or portosystemic shunting might lead 
to encephalopathy. In healthy subjects, intestinal neurotoxins, such as ammonia, manganase 
and the benzodiazepine-GABA system generated by gut bacteria from food, are transported 
by the portal vein to the liver, where 80–90% is metabolized and/or excreted immediately. 
In all subtypes of hepatic encephalopathy this process is impaired, either because 
the hepatocytes are incapable of metabolizing the neurotoxins or because portal venous 
blood bypasses the liver through collateral circulation or a medically constructed shunt. 
Neurotoxins accumulate in the systemic circulation. Ammonia plays a key role in the 
pathogenesis of HE. The small molecules of ammonia cross the blood-brain barrier and are 
absorbed and metabolized by astrocytes, population of cells in the brain that constitutes 30% 
of the cerebral cortex. Alzheimer type II astrocytes are the only cells containing glutamine 
synthetase that metabolize ammonia. It is hypothesed that glutamine synthesis within the 
astrocytes causes brain swelling.14,15 Astrocytes also provide physical and nutritional 
support for neurons, maintain the integrity of the blood–brain barrier and regulate cerebral 
blood flow.16 Ammonia also modulates glutamate neurotransmission and induces 
neurosteroid production in neurons, leading to a positive modulatory effect on the gamma-
aminobutyric acid-A receptor.17 The precise molecular mechanism(s) responsible for 
neurological alteration in HE are not known. HE is associated with alterations in the 
expression of astrocytic and neuronal genes that code for various proteins that play a critical 
role in central nervous system function including maintenance of cell volume and 
neurotransmission.14 
The pathogenesis of MHE is similar to that of HE.18-22 An increase in brain glutamine and 
brain water is pathophysiological change associated with deterioration in 
neuropsychological performance. Alterations in cerebral blood flow and glucose metabolism 
induced by ammonia are associated with a significant decrease of glucose utilization by 
various cortical regions that are involved in cognitive functions.21 The cerebral metabolic 
rate for ammonia and the permeability-surface area product for ammonia are significantly 
higher in patients with MHE.21 The increased permeability-surface area product of the 
blood–brain barrier permits ammonia to diffuse across the blood–brain barrier into the brain 
more freely than normal. This may cause ammonia-induced encephalopathy even though 
arterial ammonia levels are normal or near normal.  
Cognitive deficits observed in patients with noncirrhotic portal hypertension have also been 
linked to ammonia.18 Patients with noncirrhotic portal hypertension, such as extrahepatic 
portal venous obstruction, exhibited abnormalities in the results of neuropsychological tests, 
oral glutamine challenge test, and magnetic resonance (MR) imaging and spectroscopy 
similar to those described in HE associated with cirrhosis.22  
Other waste products implicated in hepatic encephalopathy include mercaptans (substances 
containing a thiol group), short-chain fatty acids and phenol.23 
3.2 Serotonin 
Serotonin, a neurotransmitter with widespread distribution in the CNS, is important for the 
regulation of sleep, circadian rhythmicity and locomotion. Changes in the synthesis, 
metabolism, storage and release of neuronal serotonin in HE suggest a serotonergic synaptic 
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deficit. Serotonin metabolism is exquisitely and selectively sensitive to the degree of 
portosystemic shunting and hyperammonaemia, suggesting a role for serotonin in early 
neuropsychiatric symptoms of HE.24 
3.3 Branched-chain amino acids (BCAA) and false neurotransmitters 
An imbalans between aromatic aminoacids (AAA) (phenylalanine, tryptophan and tyrosine) 
and branched-chain amino acids (BCAA)(leucine, isoleucine and valine) has been described 
in patients with severe liver dysfunction. AAA and BCAA share a common transport 
mechanism into the CNS. AS a consequence of increased concentration of AAA, neuronal 
levels may be raised leading to the production of false neurotransmitters (octopamide and 
phenylethanolamide)25 with subsequent development of HE.26 
3.4 Zink 
Zinc is a substrate of urea cycle enzymes. It may be depleted in patients with cirrhosis. Zinc 
supplementation increases the activity of ornithine transcarbamalyse increasing excretion of 
ammonia ions. There is conflicting clinical data regarding zinc supplementation in the 
management of HE.27,28,29 
3.5 Manganese 
Manganese is a neurotoxin that accumulates in the brains of patients with cirrhosis and 
portosystemic shunts.30,31 Levels of manganase correlate with hyperintensity of nucleus 
pallidus seen on MR brain scans of patients with cirrhosis. These patients may also 
demonstrate extrapyramidal signs, suggesting that altered homeostasis of manganese and 
other minerals could be responsible for the cognitive deficits associated with liver cirrhosis. 
3.6 Systemic inflammatory response 
Iinflammatory response may be important factor that may contribute to the development of 
MHE and its progression to OHE. Inflammation elsewhere in the body may precipitate 
encephalopathy through the action of cytokines and bacterial lipopolysaccharide on 
astrocytes.32 A recent study reported that severity of MHE was independent of severity of 
liver disease and levels of blood ammonia but markers of inflammation (higher neutrophil 
counts, C-reactive protein levels, and interleukin-6 levels) were significantly higher in those 
with MHE compared to those without MHE.33 Same authors showed that induced 
hyperammonemia resulted in significantly greater deterioration in psychometric tests in 
cirrhotic patients who had an ongoing infection compared with those in whom the infection 
had resolved.34 These two studies suggest that inflammation plays a synergistic role with 
ammonia in producing and modulating MHE. 
3.7 Intestinal flora 
Intestinal flora and endotoxins are another link between inflamation, ammonia and MHE. 
Imbalance of intestinal flora among cirrhotics compared to normal healthy controls has been 
demonstrated in the study of Zhao et al.35 They found increase in the counts of aerobes 
(such as Enterobacter and Enterococcus) and anaerobes (such as Clostridium) and a decrease in 
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the count of Bifidobacterium. The severity of imbalance in intestinal flora matched the degree 
of liver dysfunction. Liu et al.36 reported that cirrhotic patients with MHE had substantial 
derangements in the gut microecology, with significant fecal overgrowth of potentially 
pathogenic Escherichia coli and Staphylococcus species. Treatment with synbiotics significantly 
increased the fecal content of non-urease-producing Lactobacillus species at the expense of 
these other bacterial species. Such modulation of gut flora was associated with a significant 
reduction in blood ammonia levels and reversal of MHE in 50% of patients. Synbiotic 
treatment was also associated with a significant reduction in endotoxemia. The CTP 
functional class improved in nearly 50% of the patients. 
4. Clinical characteristics 
OHE is traditionally classified into four grades according to the West Haven criteria (Table 2).6 
Grade 0  Lack of detectable changes in personality or behavior 
  No asterixis 
Grade 1  Trivial lack of awareness 
  Euphoria or anxiety 
  Shortened attention span 
  Impaired performance of addition 
  Asterixis may be present 
Grade 2  Lethargy or apathy 
  Minimal disorientation for time or place 
  Subtle personality change 
  Inappropriate behavior, slurred speech 
  Impaired performance of subtraction 
  Asterixis is present 
Grade 3  Somnolence to semi-stupor, but responsive to verbal stimuli 
  Confusion 
  Gross disorientation 
  Asterixis is usually absent 
Grade 4  Coma (unresponsive to verbal or noxious stimuli) 
Adapted from Mullen KD6 
Table 2. West Haven criteria for semiquantitative grading of mental state 
Patients with MHE have a normal neurological examination; however they may still be 
symptomatic. Symptoms relate to disturbances in sleep, memory, attention, concentration 
and other areas of cognition.37,38 A classic sign of HE is a sleep disturbance. On a sleep 
questionnaire, disturbance is seen in 47% of cirrhotics compared to 4.5% of controls.37 A 
higher frequency of sleep disturbance in cirrhotic patients with MHE has been confirmed in 
studies using HRQOL questionaires.39,40 Sleep disturbance in cirrhosis is not associated with 
cognitive impairment; thus it may not truly be an MHE symptom. Unsatisfactory sleep is 
associated with higher scores for depression and anxiety, raising the possibility that the 
effects of chronic disease may underlie the pathogenesis of sleep disturbance.41 Disturbances 
in cirrhotics may also be related to abnormalities of circadian rhythm. 
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Defective memory may be a signe of MHE. Patients with MHE have impaired short- and 
long-term memory.38 This impairment is predominantly related to deficits in attention and 
visual perception. Memory deficit of MHE seems to comprise short-term but not long-term 
memory impairment. This can be described as an encoding defect, in which memory recall 
(or retrieval) is intact. 
Several cognitive statements (i.e. complaints), have predictive value for MHE, including 
impaired psychomotor performance (‘I have difficulty doing handwork; I am not working at 
all’); impaired sleep or rest (‘I spend much of the day lying down in order to rest’); 
decreased attention (‘I am confused and start several actions at a time’); and poor memory 
(‘I forget a lot; for example, things that happened recently, where I put things, etc.’).41 
5. Health-related quality of life 
5.1 Effect of MHE on daily functioning 
MHE adversely affects HRQOL. Cognitive impairment in MHE mainly affects complex 
activities involving attention, information processing and psychomotor skills such as 
driving a car, planning a trip, etc. whereas basic activities of daily life, such as shopping, 
dressing, personal hygiene, etc. are preserved.39,42,43 Patients with MHE had a significant 
impairment of daily functioning, such as social interaction, alertness, emotional behavior, 
sleep, work, home management, recreation and pastimes compared with cirrhotic patients 
who did not have MHE.39,42 Treatment with lactulose improved both cognitive functions 
and HRQOL; improvement in the latter was linked to improvement in cognitive function.39 
5.2 Effect of MHE on driving 
MHE adversely affects driving skills. Patients with MHE have higher rates of traffic 
violations and motor vehicle accidents.41 Schomerus et al.44 were the first to demonstrate a 
negative effect of psychomotor deficits in patients with MHE on driving fitness. Similar 
results were reported by Watanabe et al.45 Wein et al.46 found that the fitness to drive a car 
was impaired in cirrhotic patients with MHE using a standarizad 90-minute on-road driving 
test. Increased risk of automobile accidents was related to a decline in cognitive function.47 
Impairment in attention and speed of mental processing adversely affects an individual’s 
ability to react to unexpected traffic conditions. Patients with MHE have higher rates of 
traffic violations and motor vehicle accidents.47-50 Patients with MHE also had impaired 
navigation skills.51 Navigation, required for safe driving, is a complex process that depends 
on functioning working memory, attention, and speed of mental processing; impairment in 
navigation skills correlated with impairment in response inhibition and attention. 
6. Diagnosis of MHE 
The absence of clinical evidence of hepatic encephalopathy is key to the diagnosis of MHE 
and can only be determined by a detailed assessment of the patient history and a 
comprehensive neurological assessment of consciousness, cognitive, and motor function.  
Various tools have been evaluated for the diagnosis of MHE and include the 
neuropsychological tests, computerized tests, short neuropsychological and computerized 
test batteries and neurophysiological tests. Regional cerebral blood flow changes,52 and 
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magnetic resonance imaging and spectroscopy,53 though useful for understanding 
pathogenic mechanisms, are currently not considered of diagnostic value. 
6.1 Neuropsychological tests  
Neuropsychological testing is an established methodology for quantifying cognitive 
impairment due to various forms of encephalopathy, including low-grade or minimal 
hepatic encephalopathy. Neropsychological tests directly measure cognitive functions that 
are directly relevant to activities of daily living. They have been applied for the diagnosis of 
HE for more than 50 years. In the fifties, measures like the construction or reproduction of a 
fivepointed star (Fig.1.) or a coil and handwriting have been used for the diagnosis of HE. 
Someties even more complex figures were presented to the patients to be reproducted. 
Although all tests were able to depict an increase or decrease of the constructional ability of 
a patients it was extremely difficult to quantify the test result. In general, psychometric tests 
have to fulfill the following criteria: they have to be objective, reliable, valid and sensitive.54 
 
Fig. 1. Star construction test 
The neuropsychological features of MHE point to a disorder of executive functioning, 
particularly selective attention, visuospatial abilities and fine motor skills .4 Although these 
domains are most commonly implicated in MHE, impairments of memory have also been 
reported.55,56 
The attentional impairments in MHE are observed on a variety of measures. These include 
measures of cognitive processing speed involving psychomotor responding, such as the 
Number Connection test A (NCT- A), the Number Connection test B (NCT- B), block design 
test (BDT),the Digit Symbol test (DST), Line drawing test, Circle dotting, Serial-dotting test 
(SDOT), Figure connection test. Impairments on measures of cognitive processing speed and 
response inhibition that do not require a motor response have also been reported (e.g. with 
verbal fluency tasks and measures such asthe Stroop test).57-60 Visuospatial impairments 
have been primarily reported on block design tasks39,61-63 (which also include a 
motor/practic component), but also on more pure measures of visuospatial perception, such 
as line orientation or the Hooper test.64,65 Fine motor skill impairments have been noted on 
measures such as the grooved pegboard task,57,58 and on line tracing tasks (the latter also 
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Psychometric test batteries that shall be used for the diagnosis of MHE ought to examine 
exactly the fields of cognition: visual perception, visuo-spatial orientation, visual 
construction, concentration, attention and memory.29  
The small number of neuropsychological tests represent the cerebral disfunction of MHE. 
This were: the Number Connection test A (NCT- A), the Number Connection test B (NCT- 
B), block design test (BDT),the Digit Symbol test (DST), Line drawing test, Circle dotting. 
Time-tested with well recognized clinical significance, established.  
The number connection test (NCT) is the most widely used test in the psychometric 
assessment of cirrhotic patients. It was found to be capable of detecting mild mental 
dysfunction in cirrhotic patients. 
The NCT-A (Fig.2) is a test of visuo-spatial orientation and psychomotor speed. The subject 
is shown a sheet of paper with 25 numbered circles which are randomly spread over the 
paper. The task is to connect the circles from 1-25 as quick as possible. Test result is the time 
needed by the subject including error correction time.68  
 
    
Fig. 2. Number Connection test A (NCT-A)68     Fig. 3. Number Connection test B (NCT– B)68 
The NCT-B (Fig.3) is quite similar.The circles include the numbers from 1-13 and the letters 
from A-L. The subjects are asked to connect numbers and letters in alternating manner, that 
means go from 1-A-2-B-3-C and so on. Test result is the time needed including error 
correction time. Besides visuo-spatial orientation and psychomotor speed this test is 
appropriate to study the ability to shift attention.68  
The Block Design Test (BDT) is a test of visuo-spatial and motor skills (Fig.4). The task is to 
take 6- 9 blocks that have all white sides, all red sides, and red and white sides and arrange 









Fig. 4. The Block Design Test (BDT)69 
The Digit Symbol test (DST) (Fig. 5) - the subject is given a series of double-boxes with a 
number given in the upper part. The task is to draw a symbol pertinent to this number into 
the lower part of the boxes. Nine fixed pairs of numbers and symbols are given at the top of 
the test sheet. Test result is the number of boxes correctly filled within 90 seconds. 
Pathological test results indicate a deficit in visuo-constructive abilities, especially.70 
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The line drawing test (Fig. 6) is a test of motor speed and accuracy. The patients have to 
follow the route of this labyrinth without crossing or even touching the borderlines.70 
 
Fig. 6. The line drawing test 
For the assessment of the test result the whole route is devided into small sections (Fig.7) 
and each touching or crossing the border in a section is counted. The number of mistakes 
and the time needed to go through the labyrinth, both, are test results.70 
 
 
Fig. 7. Division of the whole route of the line drawing test for the assessment of the errors. 
The circle dotting test (Fig.8) is the most simple test of the battery. It is a test of pure motor 
speed. The subjects are asked to put a dot in each of the 100 circles given on the sheet, after 









Fig. 8. The circle dotting test 
The Working Party recommends that the diagnosis of MHE requires a normal mental status 
examination and impairment in the performance of at least two of the following tests: NCT-
A, or figure connection test-A (FCT-A), NCT-B, BDP, DST.41 
In 2009, the Commission on Neuropsychological Assessment of Hepatic Encephalopathy 
concluded that neuropsychological test batteries aimed at measuring multiple domains of 
cognitive function are generally more reliable than single tests, and tend to be more strongly 
correlated with functional status.71 Both the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS)72 and PSE-Syndrom-Test73 may be used for this 
purpose. 
The PSE-Syndrom-Test, developed in Germany and validated in several other European 
countries, incorporates older assessment tools such as NCT-A and NCT-B, the line-tracing 
test (LTT), the serial-dotting test (SDT), and DST.  
The psychometric hepatic encephalopathy score (PHES) is a standardized test battery 
including NCT-A and B, the line-tracing test for time (t) and error (e), the serial-dotting test, 
and the digit symbol test. This battery examines many of the abnormalities seen in patients 
with MHE, including motor speed and accuracy, visuo-spatial orientation, visual 
perception, visual construction, attention, concentration, and, to a lesser extent, memory. 
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The RBANS contains measures of verbal and visual anterograde memory, working memory, 
cognitive processing speed, language (including semantic fluency) and visuospatial function 
(line orientation and figure copy). It is a portable pencil-and-paper test that requires a 
folding stimulus booklet and paper record form to administer. Administration time is 
approximately 20–25 min.71 In the study of Sorrel et al.76 RBANS scores were strongly 
correlated with liver disease as measured by the model for end-stage liver disease staging. 
Scores on the RBANS also predicted disability independently of liver disease severity in this 
study. 
Use of either the RBANS or the PSE-Syndrom-Test is recommended for diagnosing and 
monitoring minimal hepatic encephalopathy. The choice of which battery to use should be 
based upon the availability of local translations and normative data.71 
6.2 Neurophysiological tests  
Quantitative neurophysiologic tools include Simple electroencephalography (EEG), evoked 
potentials (auditory, visual, Somatosensory) and P300 (type of auditory evoked potential). 
Changes in EEG/evoked responses are non-specific. 
The major finding on EEG is a general decrease in wave frequency and an increase in wave 
amplitude. First, socalled theta-waves with a frequency between 4 and 7 cps occur, then 
these theta waves predominate and are committed by delta waves with a frequency of 1-3 
cps. Preterminally there is a loss of wave amplitude and a flattening of the curve. These 
abnormalities may be found even in cirrhotics without clinical signs of encephalopathy. 
There is no close correlation between the grade of HE and the degree of EEG 
abnormalities.70 The sensitivity of the EEG for the diagnosis of subclinical HE is limited 
compared to psychometric tests.70 The EEG is useful for follow-up examinations, 
predominantly.  
 Among EEG variations, the most sensitive test is computer-assisted analysis, including the 
mean dominant EEG frequency and the power of a particular rhythm.77,78 Quantified-EEG 
has a prognostic value for occurrence of bouts of overt HE and mortality in cirrhotic 
patients.78  
Evoked potentials are subdivided into the group of exogenous evoked potentials and 
endogenous evoked potentials. The exogenous evoked potentials like the flash or 
checkerboard visual evoked potentials (VEP), brainstem auditory evoked potentials (BAEP) 
and somatosensory evoked potentials are used to examine the function of sensory 
pathways. The endogenous evoked potentials are measures of cognitive function. In the 
only study that compares the different exogenous evoked potentials for their diagnostic 
ensitivity in hepatic encephalopathy, the BAEP were the most sensitive measure for the 
diagnosis of HE.79  
Among evoked responses, the P300 peak obtained in an auditory oddball paradigm is the 
most sensitive test.80-83 These tests can supplement neurological or neuropsychiatric 
examination. It has been demonstrated that there was a greater likelihood of development of 
overt HE in cirrhotic patients with abnormal P300 event-related potential latencies and NCT 
than in patients with no such abnormality.80  
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Neurophysiological tests can be used during follow up to demonstrate change in a patient’s 
condition. Their major limitations are: (i) need for specialized equipment and technical 
expertise for evaluation and interpretation; and (ii) inability to perform these tests in an 
outpatient clinic.41 
The changes observed in cerebral blood flow and metabolism in SPET, PET, and 1H and 31P 
MRS studies reflect the pathogenic process that underlies the condition rather than 
providing diagnostic information. Similarly, the morphological brain abnormalities 
identified in this population, including mild brain oedema, hyperintensity of the globus 
pallidus and other subcortical nuclei observed in cerebral MR studies, and the central and 
cortical atrophy observed in neural imaging studies, are unlikely to have diagnostic utility.4  
6.3 Computerized tests  
Computerized psychometric tests measuring both the reaction time and the accuracy of 
performing tasks requiring psychomotor speed, attention, short-term memory, or choice ability.  
Critical flicker frequency (CFF) tests the ability of a patient to perceive flickering and its 
fusion threshold. The CFF threshold measures visual discrimination and general arousal.84 
CFF is a simple, reliable and accurate method for the diagnosis of MHE. The technique 
shows little dependence on age, education or training.75,85  
Inhibitory control test (ICT) is a computerized test of attention and response inhibition that 
has been used to characterize attention deficit disorder, schizophrenia and traumatic brain 
injury. ICT has been validated for the diagnosis of MHE in USA and found to be reliable and 
sensitive for detection as well as follow-up of patients with MHE.86  
6.4 Magnetic resonance imaging and spectroscopy 
Magnetic resonance imaging (MRI) identified the morphological brain abnormalities in the 
population of patients with cirrhosis, including mild brain oedema, hyperintensity of the 
globus pallidus and other subcortical nuclei, and central and cortical atrophy. High-signal 
abnormalities on T1-weighted images in the globus pallidum have been observed in 
cirrhotic patients, even without clinical evidence of HE. Deposition of manganese is 
regarded as the most likely explanation of this high-signal abnormality.87 There is no direct 
correlation between pallidal hyperintensity and grade of encephalopathy.88 Basal ganglia 
T1-weighted signal intensity and manganese accumulation appear to be related to the 
underlying degree of portal-systemic shunting rather than directly to neuropsychiatric 
impairment.90 Hyperintense globus pallidus on MRI is common in patients with liver 
cirrhosis and also occurs in patients with noncirrhotic portal hypertension. 
Magnetic resonance spectroscopy (MRS) shows a decrease in myo-inositol/creatine and 
choline/creatine ratios in the white matter with an increase in the Glx (glutamine and 
glutamate) concentration in the basal ganglia in patients with MHE.91,92 Liver 
transplantation as well as lactulose therapy have been shown to reverse these changes at 4 
weeks and later after transplantation.91 However, the ability of MRS to differentiate between 
cirrhotic patients without HE and those with MHE has not been conclusively shown.41 
Diffusion-weighted imaging allows assessment of intracellular and extracellular water 
content in the brain, which helps in differentiating cytotoxic from vasogenic edema.93 
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Diffusion tensor imaging has revealed that mean diffusivity, a measure of water movement 
across cell membranes, is significantly higher in patients with MHE in the regions of the 
corpus callosum, internal capsules, caudate nuclei and occipital white matter. Increase in 
mean diffusivity indicates the presence of interstitial brain edema. Mean diffusivity values 
increase as the grade of HE increases, suggesting that brain edema present in patients with 
HE may contribute to its pathogenesis.94 Mean diffusivity values decreased significantly and 
there was a corresponding improvement in neuropsychological test scores in patients with 
MHE after three weeks of lactulose therapy.94 MR imaging techniques therefore complement 
neuropsychological evaluation of MHE.41 
7. Diagnostic criteria for MHE 
The diagnostic criteria for MHE have not been standardized but rest on careful patient 
history and physical examination, normal mental status examination, demonstration of 
abnormalities in cognition and/or neurophysiological function, and exclusion of 
concomitant neurological disorders.  
No consensus on diagnostic criteria or diagnostic tests has been established. 
 Cirrhotic patients 
 Without clinical signs of encephalopathy  
 Perform worse in psychometric tests when compared with healthy controls 
 Affects an estimated 60% (50% to 80%)* of patients with cirrhosis 
 Cerebral dysfunction has a major impact on patients’ daily living 
 The presence of a disease that can cause MHE, such as, cirrhosis and/or the 
presence of a portalsystemic shunt 
 normal mental status on clinical examination 
 demonstration of abnormalities of cognition and/or neurophysiological variables 
 exclusion of concomitant neurological disorders. 
The INASL Working Party recommends that all patients with cirrhosis be screened for the 
presence of MHE using a standard battery of psychometric tests, PHES, CFF or ICT, 
depending upon the availability of tests and their validation for local populations from 
different parts of the world (Fig. 1). Patients whose index psychometric or computerized test 
results do not indicate pathology should be screened every 6–12 months. 
It has been shown conclusively that cognitive functions improve with therapy for MHE.3,62–67 
Such therapy may improve HRQOL of patients with MHE3,67 and delay the development of 
HE.68 Hence all patients with liver cirrhosis should be subjected to testing for MHE. Special 
attention should be given to those who have cognitive symptoms and high-risk groups such 
as active drivers, patients handling heavy machines or reporting decline in work 
performance. 
8. Natural history 
8.1 Development of overt hepatic encephalopathy 
Patients with MHE may improve, remain unchanged or deteriorate and develop overt HE 
over a long-term follow-up. 
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The frequency of MHE increases as the severity of liver disease increases.4,13–16,18,22 In 
view of a high frequency of MHE in patients with liver disease, it is important to understand 
its impact on future clinical outcomes, such as occurrence of overt HE, quality of life and 
survival, and to determine whether treatment of MHE can induce improvements in these 
outcomes. 
Several studies that looked at the frequency of development of overt HE in cirrhotic patients 
found that those with MHE developed overt HE more often during follow up than those 
without MHE (Table 4).4,15,17,20,48,88,89 In addition, some studies have shown an 
increased risk of death in patients with liver cirrhosis and MHE compared to those without 
MHE (Table 4).20,22,88 However, patients with MHE had poorer liver function than those 
without MHE in these studies, making it difficult to ascribe the poor outcome to the 
presence of MHE. Das et al.4 studied the relationship of progression of MHE to overt HE in 
relation to the severity of liver dysfunction and found that the rate of progression to overt 
HE was much higher in patients with MHE and a CTP score 6 than in those with MHE 
and a CTP score _ 6. Amodio et al.88 found that the presence of MHE and that of liver 
dysfunction were both associated with mortality on univariate analysis; however, on 
multivariate analysis, liver functional status was the only independent predictor of 
mortality. In another study, progression of MHE to overt HE was associated with abnormal 
response to oral glutamine challenge, which in turn was associated with poor liver 
function.90 Furthermore, MHE in patients with preserved liver function but large portal-
systemic shunts (congenital shunts, non-cirrhotic portal hypertension and cirrhosis with 
preserved liver function) appears to have a good outcome, even though these data are based 
on a small number of patients.10 Thus, it appears that the higher risk of overt HE or death in 
patients with MHE may not be related to MHE per se but to the poorer liver function in 
patients with MHE. 
9. Survival 
Current data suggest that patients with MHE tend to have more frequent episodes of overt 
HE and poorer survival than in those without MHE, and indicate that patients with MHE 
have a more advanced liver disease. Child-Turcotte-Pugh score and PHES were associated 
with a poor prognosis 
10. Treatment 
Ammonia plays a key role in the pathogenesis of MHE Empiric therapy is based on the 
principle of reducing the production and absorption of ammonia in the gut—a number of 
agents are beneficial for this purpose. 
10.1 Nutritional interventions  
The European Society for Parenteral and Enteral Nutrition recommended, in 2006, that 
patients with cirrhosis must eat at least 1.2 g/kg of protein daily. They also recommended 
that the diet of patients with cirrhosis should be supplemented with branched-chain amino 
acids (BCAAs) and vegetable protein once HE has developed. Vegetable-based protein is 
better tolerated by patients with cirrhosis than meat-based protein . 
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10.2 Pharmacological therapy 
Non-absorbable disaccharides include lactulose and lactitol. Treatment for MHE may be 
initiated with lactulose; patients should receive 30–60 mL of lactulose in two or three 
divided doses so that they pass two to three semi-soft stools per day. Although the 
appropriate duration of therapy for MHE is unsettled, at least three studies suggest that 
treatment may be advised for 3–6 months.(3,67,95) 
Lactulose decreases blood ammonia levels, and improves psychometric performance and 
HRQOL (Table 5).3,59,62,64,67,91–95 Using cerebral diffusion tensor imaging, Kale et al.59 showed 
that interstitial brain edema observed in patients with MHE resolves after treatment for 3 
weeks with lactulose in parallel with improvements in neuropsychiatric performance. 
Prasad et al.3 studied the effect of treatment of MHE with lactulose on psychometric 
performance (measured by NCT, FCT-A, FCT-B, picture completion and block-design tests) 
and HRQOL (measured by Sickness Impact Profile [SIP]). Patients with MHE showed 
significant impairment in 11 scales of the SIP, the psychosocial and physical subscores, and 
in the total SIP. Patients received 30–60 mL of lactulose in two or three divided doses so that 
the patient passed two to three semi-soft stools per day. Following lactulose therapy for 3 
months, both psychometric performance and HRQOL improved; MHE reversed in 64.5% of 
treated patients compared with 6.7% in the no-treatment group (P 0.0001). Significant 
improvement was found in five (emotional behavior, ambulation, mobility, sleep/rest and 
recreation and pastimes) of the 12 scales of the SIP and in the total psychosocial and physical 
sub-scores in the treated patients compared with the untreated patients. Improvement in 
HRQOL was linked to improvement in cognitive function. A recent study that compared 
lactulose, a probiotic and LOLA with no treatment, confirmed these findings.67 Lactulose or 
lactitol, both non-absorbable, synthetic disaccharides with multiple effects on gut flora, are 
regarded as intestinal prebiotics.96 Dietary addition of lactulose can exert a bifidogenic effect 
accompanied by a favorable effect on colonic NH3 metabolism.97 Ameta-analysis of 
randomized trials of lactulose versus placebo or no intervention in treatment of patients 
with MHE showed that the treatment with lactulose was associated with improvement in 
psychometric (cognitive) performance.35 
Branched-chain amino acids, flumazenil, L–ornithine L–aspartate, acetyl L-carnitine, and 
probiotics/synbiotics. A majority of these attempts were aimed at reducing blood ammonia 
level, and most studies have shown improvement in psychometric measurements, ammonia 
levels, cerebral edema and health-related quality of life (HRQoL) 
10.3 Prebiotics, probiotics or synbiotics 
Prebiotics, probiotics or synbiotics (probiotics and fermentable fiber) are effective in treating 
patients with MHE,63–67 and can also be used as long-term therapy. Liu et al.65 showed that 
modulation of gut microecology and acidification of gut lumen in patients with liver 
cirrhosis and MHE by treatment with synbiotics resulted in increased fecal content of non-
urease-producing Lactobacillus species, whereas the number of urease-producing pathogenic 
Escherichia coli and Staphylococcal species decreased. This effect persisted for 14 days after 
cessation of supplementation. It was associated with a significant reduction in blood 
ammonia and endotoxin levels and reversal ofMHEin nearly 50% of the patients. The 
severity of liver disease, as assessed according to CTP class, also improved in nearly 50% of 
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the patients. In a recent randomized control trial, supplementation with probiotic yogurt 
resulted in a significant reversal ofMHEin the group receiving yogurt compared 
to no treatment.63 Treatment with a probiotic preparation also improves HROQL.67 
Prebiotics, probiotics or synbiotics are efficacious in the treatment of HE by decreasing 
bacterial urease activity, pH in the gut lumen, ammonia absorption and total ammonia in 
the portal blood, and by improving nutritional status of gut epithelium resulting in 
decreasing intestinal permeability. In addition, they help ameliorate the inflammation and 
oxidative stress in the hepatocytes, leading to increased hepatic clearance of ammonia.98 
These mechanisms may be additive or synergistic in treating MHE. Probiotics may represent 
a safe, effective, long-term therapy for MHE and may be an alternative to lactulose. 
10.4 L-ornithine–L-aspartate 
Clinical studies evaluating the role of LOLA in the treatment of MHE did not show its 
effectiveness; however, these studies were small and underpowered. A recent study that 
compared lactulose, a probiotic and LOLA with no treatment, however, showed that LOLA 
is as effective as lactulose or a probiotic preparation in improving psychometric 
performance and HRQOL.67 Larger prospective studies are warranted to evaluate the role of 
LOLA before it can be recommended for the treatment of MHE. 
10.5 Antibiotics 
The role of antibiotics in MHE has not been evaluated. Prospective studies with poorly 
absorbed antibiotics are required to evaluate their efficacy in improving MHE. 
Antibiotics: Rifaximin, Neomycin 
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